Key Highlights
- $48 per share all-cash deal values Tourmaline at $1.4B, marking one of Novartis’ most significant 2025 acquisitions.
- Pacibekitug, ready for Phase 3, an anti-IL-6 monoclonal antibody, could redefine treatment standards in cardiovascular diseases by tackling residual inflammatory risk.
- Strategic expansion for Novartis in cardiovascular, renal, and metabolic care underscores industry-wide momentum toward inflammation-targeting biologics.
A $1.4 Billion Bet on Cardiovascular Innovation
Novartis announced its agreement to acquire Tourmaline Bio for $48.00 per share in cash, representing a 59% premium over its prior closing price. The deal reflects Novartis’ conviction in Tourmaline’s lead program, pacibekitug, and the broader potential of inflammation-driven therapies to reshape cardiovascular care.
Pacibekitug: A Differentiated IL-6 Antibody, Ready for Phase 3
Tourmaline’s pacibekitug is a fully-human, long-acting anti-IL-6 monoclonal antibody that boasts high binding affinity, low immunogenicity, and a naturally long half-life. With clinical data from over 450 participants across six trials, the asset is positioned as a best-in-class candidate targeting residual inflammatory risk in atherosclerotic cardiovascular disease (ASCVD).
Novartis Strengthens Its Cardiovascular, Renal, and Metabolic (CRM) Portfolio
This acquisition builds on Novartis’ growing CRM pipeline, reinforcing its strategy of diversifying beyond traditional therapies. The integration of pacibekitug aligns with Novartis’ innovation agenda to pioneer anti-inflammatory treatments for cardiovascular disease—an area with significant unmet medical need and no widely adopted therapies today.
Industry Impact and Forward Outlook
The transaction not only elevates Novartis’ presence in cardiovascular inflammation but also signals broader biopharma interest in immune-modulating approaches. For shareholders, the deal delivers immediate value, while for patients, it holds the promise of breakthrough treatment options. Completion of the acquisition is expected in Q4 2025, subject to regulatory and customary closing conditions.
About the Companies
Novartis AG is a global leader in innovative medicines, with a focus on advancing treatments across oncology, cardiovascular, renal, metabolic, and neuroscience. The company combines cutting-edge science and digital technologies to transform patient outcomes worldwide.
Tourmaline Bio, Inc. (NASDAQ: TRML) is a late-stage clinical biotechnology company dedicated to developing transformative medicines for patients with life-altering inflammatory and immune diseases. Its lead asset, Pacibekitug, is positioned as a best-in-class therapy with potential to address unmet needs in cardiovascular and autoimmune conditions.
By
